These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 15609164)
1. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. François C; Toumi M; Aakhus AM; Hansen K Eur J Health Econ; 2003; 4(1):12-9. PubMed ID: 15609164 [TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Demyttenaere K; Hemels ME; Hudry J; Annemans L Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612 [TBL] [Abstract][Full Text] [Related]
3. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724 [TBL] [Abstract][Full Text] [Related]
4. Escitalopram: a pharmacoeconomic review of its use in depression. Croom KF; Plosker GL Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439 [TBL] [Abstract][Full Text] [Related]
5. Spotlight on the pharmacoeconomics of escitalopram in depression. Croom KF; Plosker GL CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Fantino B; Moore N; Verdoux H; Auray JP Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Hemels ME; Kasper S; Walter E; Einarson TR Curr Med Res Opin; 2004 Jun; 20(6):869-78. PubMed ID: 15200745 [TBL] [Abstract][Full Text] [Related]
8. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation. Kongsakon R; Bunchapattanasakda C J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855 [TBL] [Abstract][Full Text] [Related]
9. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Wade AG; Toumi I; Hemels ME Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113 [TBL] [Abstract][Full Text] [Related]
10. Escitalopram for the treatment of major depression and anxiety disorders. Höschl C; Svestka J Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Nordström G; Danchenko N; Despiegel N; Marteau F Value Health; 2012; 15(2):231-9. PubMed ID: 22433753 [TBL] [Abstract][Full Text] [Related]
12. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. Sullivan PW; Valuck R; Saseen J; MacFall HM CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793 [TBL] [Abstract][Full Text] [Related]
13. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Wade AG; Toumi I; Hemels ME Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821 [TBL] [Abstract][Full Text] [Related]
15. [Severe forms of depression: the efficacy of escitalopram]. Spadone C Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. Xie F; Despiegel N; Danchenko N; Hansen K Int J Psychiatry Clin Pract; 2009; 13(1):59-69. PubMed ID: 24946123 [TBL] [Abstract][Full Text] [Related]
17. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Bose A; Korotzer A; Gommoll C; Li D Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245 [TBL] [Abstract][Full Text] [Related]
18. Escitalopram therapy for major depression and anxiety disorders. Baldwin DS; Reines EH; Guiton C; Weiller E Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Llorca PM; Azorin JM; Despiegel N; Verpillat P Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]